AELIS FARMA BUY | EUR21 More evidence around Cannabis’s psychiatric impact and FDA’s renewed focus on SUD…
º FDA pushing for OTC Naloxone as a wide opioid campaign highlights FDA’s renewed focus on fighting substance abuse disorder… We believe this trend bodes well for AELIS’s commercial success…New Nature publication demonstrated that cannabis use could cause delusional experiences… Especially, it is problematic for the young population… We believe the market to wake up to reality very soon…
Re-iterating Buy rating with a TP of EUR 21
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.